Lisaftoclax (APG-2575) Safety and Activity As Monotherapy or Combined with Acalabrutinib or Rituximab in Patients (pts) with Treatment-Naïve, Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL): Initial Data from a Phase 2 Global Study

MLA

Davids, Matthew S., et al. “Lisaftoclax (APG-2575) Safety and Activity As Monotherapy or Combined with Acalabrutinib or Rituximab in Patients (Pts) with Treatment-Naïve, Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL): Initial Data from a Phase 2 Global Study.” Blood, vol. 140, no. Supplement 1, Nov. 2022, pp. 2326–28. EBSCOhost, https://doi.org/10.1182/blood-2022-160386.

APA

Davids, M. S., Chanan-Khan, A., Mudenda, B., Nogaieva, L., Kriachok, I., Usenko, H., Ivanov, V., Kyselova, O., Perekhrestenko, T., Muzhychuk, I., Myasnikov, A., Maslyak, Z., Proidakov, A., Uspenskaya, O., Borisenkova, E., Marlton, P., Siddiqi, T., Winter, A., Lysa, T., … Zhai, Y. (2022). Lisaftoclax (APG-2575) Safety and Activity As Monotherapy or Combined with Acalabrutinib or Rituximab in Patients (pts) with Treatment-Naïve, Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL): Initial Data from a Phase 2 Global Study. Blood, 140(Supplement 1), 2326–2328. https://doi.org/10.1182/blood-2022-160386

Chicago

Davids, Matthew S., Asher Chanan-Khan, Boyd Mudenda, Larysa Nogaieva, Iryna Kriachok, Hanna Usenko, Vladimir Ivanov, et al. 2022. “Lisaftoclax (APG-2575) Safety and Activity As Monotherapy or Combined with Acalabrutinib or Rituximab in Patients (Pts) with Treatment-Naïve, Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL): Initial Data from a Phase 2 Global Study.” Blood 140 (Supplement 1): 2326–28. doi:10.1182/blood-2022-160386.